In summary proceedings brought by Grünenthal against Teva regarding Grünenthal’s European patent EP 1 457 208 on testosterone depot compositions, the Dutch court ruled in favor of Grünenthal on 3 October.
Teva must further refrain from direct and indirect infringement. This ruling is remarkable especially since the same patent was found invalid in proceedings in the United Kingdom and Germany. Martin Klok (V.O.) assisted Grünenthal as patent attorney.
Testosterone depot compositions are administered to individuals who are deficient in testosterone in order to raise their testosterone levels to physiological levels. The composition patented by Grünenthal only needs to be administered once every three months by intramuscular injection. In contrast, products already on the market had to be administered once every two or three weeks.
Read the decision (in Dutch) here.